Drug Trial Radar · NCT05607550
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
398
Actual
Start
Jun 1, 2023
Primary completion
Oct 6, 2026
Study completion Feb 15, 2028
Sponsor
- Lead sponsor
- ArriVent BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Allist Pharmaceuticals, Inc.
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Conditions
- Metastatic Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- EGFR Exon 20 Mutations
Interventions
furmonertinib 240 mg oral, dailyDrug
furmonertinib tablet
furmonertinib 160 mg oral, dailyDrug
furmonertinib tablet
platinum-based chemotherapyDrug
(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) determined by blinded independent central review (BICR)Time frame: Up to 32 months after first dose
Locations
208 sites in 19 countries. Site status is shown where the registry gives one.
Arrivent Investigative Site
Daphne, Alabama
Arrivent Investigative Site
Yuma, Arizona
Arrivent Investigative Site
Fayetteville, Arkansas
Arrivent Investigative Site
Beverly Hills, California
Arrivent Investigative Site
Fullerton, California
Arrivent Investigative Site
Long Beach, California
Arrivent Investigative Site
Los Alamitos, California
Arrivent Investigative Site
Napa, California
Arrivent Investigative Site
Orange, California
Arrivent Investigative Site
Orange, California
Arrivent Investigative site
Sacramento, California
Arrivent Investigative Site
San Diego, California
Arrivent Investigative Site
Santa Barbara, California
Arrivent Investigative Site
Santa Monica, California
Arrivent Investigative Site
Santa Rosa, California
Arrivent Investigative Site
Whittier, California
Arrivent Investigative Site
Hartford, Connecticut
Arrivent Investigative Site
Norwich, Connecticut
Arrivent Investigative Site
Fort Myers, Florida
Arrivent Investigative Site
St. Petersburg, Florida
Arrivent Investigative Site
The Villages, Florida
Arrivent Investigative Site
Peoria, Illinois
Arrivent Investigative Site
Rolling Meadows, Illinois
Arrivent Investigative Site
Fort Wayne, Indiana
Arrivent Investigative Site
Indianapolis, Indiana
Arrivent Investigative Site
South Bend, Indiana
Arrivent Investigative Site
Bethesda, Maryland
Arrivent Investigative Site
Frederick, Maryland
Arrivent Investigative Site
Rockville, Maryland
Arrivent Investigative Site
Fairhaven, Massachusetts
Arrivent Investigative Site
Lansing, Michigan
Arrivent Investigative Site
Bolivar, Missouri
Arrivent Investigative Site
Kansas City, Missouri
Arrivent Investigative Site
Saint Joseph, Missouri
Arrivent Investigative Site
St Louis, Missouri
Arrivent Investigative Site
Omaha, Nebraska
Arrivent Investigative Site
Belleville, New Jersey
Arrivent Investigative Site
Englewood, New Jersey
Arrivent Investigative Site
Florham Park, New Jersey
Arrivent Investigative Site
The Bronx, New York
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.